Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey

Neuroscience

Volumn 44, Issue 3, 1991, Pages 591-605

  Pifl, Ch ^a   Schingnitz, G ^b   Hornykiewicz, O ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN MONOAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; MONKEY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMAL; BRAIN MAPPING; CORPUS STRIATUM; DOPAMINE; FEMALE; HIGHER NERVOUS ACTIVITY; MACACA MULATTA; MALE; NOREPINEPHRINE; PARKINSON DISEASE, SECONDARY; SEROTONIN; SUBSTANTIA NIGRA;

EID: 0025781009     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(91)90080-8     Document Type: Article

References (98)

1. Permanent human Parkinsonism due to l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases
2. Reversal of experimental Parkinsonism by lesions of the subthalamic nucleus
3. Brain dopamme and the syndromes of Parkinson and Huntington
4. Regional distribution of catecholamines in monkey cerebral cortex, evidence for a dopaminergic innervation of the primate prefrontal cortex
5. + can disrupt the nigrostriatal dopamine system by acting in the terminal area
6. Behavioral and biochemical studies in monkeys made hemiparkinsonian by MPTP
7. A direct role of dopamine in the rat subthalamic nucleus and an adjacent intrapeduncular area
8. Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates
9. A primate model of Parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine
10. The clinical syndrome of striatal dopamine deficiency: Parkinsonism induced by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP)
11. On the aetiology of Parkinson's disease
12. Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-l,2,3,6-tetrahydropyridine in the rat
13. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues
14. A dopaminergic cell line variant resistant to the neurotoxin l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
15. Preferential vulnerability of A8 dopamine neurons in the primate to the neurotoxin l-methyl-4-phenyl-l,2,3,6-tetra-hydropyridine
16. Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys
17. 16F-l-DOPA imaging of the dopamine neostriatal system in normal and clinically normal MPTP-treated rhesus monkeys
18. Distribution of free and conjugated dopamine in monkey brain, peripheral tissues and cerebrospinal fluid determined by high-performance liquid chromatography
19. Differential responsiveness to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine toxicity in sub-regions of the primate substantia nigra and striatum
20. Effects of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSF
21. MPTP reduces dopamine and norepinephrine concentrations in the supplementary motor area and cingulate cortex of the primate
22. Acute administration of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) reduces dopamine and serotonin but accelerates norepinephrine metabolism in the rat brain. Effect of chronic pretreatment with MPTP
23. Noradrenaline distribution in subcortical areas of the human brain
24. Determination of catecholamines in rat brain parts by reverse-phase ion pair liquid chromatography
25. + followed by biochemical and functional analysis
26. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys
27. Inhibition of types A and B monoamine oxidase by l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
28. l-Methyl-4-phenyl-l,2,3,6-tetrahydro-pyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost?
29. The dopamine neurotoxin l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces histological lesions in the hypothalamus of the common marmoset
30. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys
31. The brain-stem lesions in Parkinsonism
32. MPTP alters central catecholamine neurons in addition to the nigrostriatal system
33. Neurotoxicity of the meperidine analogue jV-methyl-4-phenyl-l,2,3,6-tetrahydropyridine on brain catecholamine neurons in the mouse
34. Zur Pathologie der Paralysis Agitans und des post-enzephalitischen Parkinsonismus
35. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study
36. The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and primate models of Parkinson's disease: a novel approach to treatment
37. Biochemical pathophysiology of Parkinson's disease
38. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): behavior and histology
39. 3,4-Methylenedioxymethamphetamine (“Ecstasy”) selectively destroys brain serotonin terminals in rhesus monkeys
40. The evolution of nigrostriatal neurochemical changes in the MPTP-treated squirrel monkey
41. JV-Methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) causes destruction of the nigrostriatal but not the mesolimbic dopamine system in the monkey
42. l-Methyl-4-phenyl-I,2,3,6-tetrahydropyridine-induced neurotoxicity in the rat: characterization and age-dependent effects
43. The actions of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease
44. Effects of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine in the dog: effect of pargyline pretreatment
45. Differences in the metabolism of MPTP in the rodent and primate: parallel differences in sensitivity to its neurotoxic effects
46. +) from rat striatal neurons in vitro
47. Participation of brain monoamine oxidase B form in the neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine: relationship between the enzyme inhibition and the neurotoxicity
48. The neurotoxicity of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its relevance to Parkinson's disease
49. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease
50. Injury of nigral neurons exposed to l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine: a tyrosine hydroxylase immunocytochemical study in monkey
51. MPTP effects on dopamine neurons
52. MPTP-induced parkinsonian syndromes in humans and animals
53. Use of 6-hydroxydopamine to deplete brain catecholamines in the rhesus monkey: effects of urinary catecholamine metabolites and behavior
54. Parkinsonism induced by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease
55. Chronic Parkinsonism in humans due to a product of a meperidine-analog synthesis
56. Selective nigral toxicity after systemic administration of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey
57. MPTP current concepts and controversies
58. Intraneuronal generation of a pyridinium metabolite may cause drug-induced Parkinsonism
59. Neurochemical investigations in vitro with 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) in preparations of rat brain
60. Imaging of dopamine systems in human subjects exposed to MPTP
61. In vivo effect of MPTP on monoamine oxidase activity in mouse striatum
62. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the Macaque monkey include the ventral tegmental area and the locus coeruleus
63. MPP+ (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons
64. Similarity and dissimilarity of MPTP models to Parkinson's disease: importance of juvenile Parkinsonism
65. Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
66. The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease
67. Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain
68. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets
69. Oxidation of the neurotoxic aminé1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP
70. Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP)
71. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease
72. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys
73. Deficits in opérant behavior in monkeys treated with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
74. Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP): behavior, histology, and biochemistry
75. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP
76. MPTP-induced Parkinsonism in monkeys: mechanism of action, selectivity and pathophysiology
77. Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism
78. Deficits in reaction times and movement times as correlates of hypokinesia in monkeys with MPTP-induced striatal dopamine depletion
79. Brain monoamines in the rhesus monkey during long-term neuroleptic administration
80. +
81. Interactions of the neurotoxic amine 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine with monoamine oxidases
82. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias Lecture
83. Simultaneous determination of serotonin, 5-hydroxyindole acetic acid, 3,4-dihydroxyphenylacetic acid and homovanillic acid by high performance liquid chromatography with electrochemical detection
84. Dopamine depletion in rat brain by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
85. Intellectual changes in patients with MPTP-induced Parkinsonism
86. Intellectual changes in asymptomatic MPTP-exposed subjects
87. Cognitive change following MPTP exposure
88. Neuropathological study on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of the crab-eating monkey
89. Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys
90. Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3.6-tetrahydropyridine (MPTP)
91. Further treatment with MPTP does not produce Parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin
92. Effect of 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine (MPTP) on monoamine neurotransmitters in mouse brain and heart
93. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset
94. Age-related changes in multiple neurotransmitter systems in the monkey brain
95. Distinct monoamine oxidase A and B populations in primate brain
96. Animal models of Parkinsonism using selective neurotoxins: clinical and basic implications